Nevertheless, a meta-analysis of multiple clinical trials may be useful for evaluating whether SGLT2 inhibitors reduce the incidence of SCD, which is not expected to be as common an event as the development of heart failure or chronic kidney disease. This evidence concerns the gene SLC5A2 and Schnyder corneal dystrophy.